Dashboard
Investment deals 
Investor briefings
Company alerts
Investment news
Investment videos
Stock trackerCompany alerts
Stealth BioTherapeuticsStealth BioTherapeutics (NAS: MITO)
LT 2419419 of 523Stealth BioTherapeutics is an innovative biopharmaceutical company developing therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of aging. Our team works with patients and advocacy organizations to better understand their journey with mitochondrial disease and raise awareness of the unmet need our programs seek to address.Longevity pillar- Treatment
- Prevention
Longevity domain:- Longevity drugs
- Neuropharma
- Discovery platforms
Longevity target: Aging Driver, Aging Disease and Pharmanovia partner for commercialisation of elamipretide.
Stealth BioTherapeutics (NAS: MITO)
LT 2419
419 of 523
Stealth BioTherapeutics is an innovative biopharmaceutical company developing therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of aging. Our team works with patients and advocacy organizations to better understand their journey with mitochondrial disease and raise awareness of the unmet need our programs seek to address.
Longevity pillar
- Treatment
- Prevention
Longevity domain:
- Longevity drugs
- Neuropharma
- Discovery platforms
Longevity target: Aging Driver, Aging Disease
Stealth BioTherapeutics has made an exclusive licensing agreement with Pharmanovia for the commercialisation of its elamipretide to treat Barth syndrome. Pharmanovia will hold exclusive rights for the commercialisation of elamipretide in the EU, other European countries including Switzerland, Norway, Iceland and the UK, and the Middle East and northern Africa region. The agreement allows Stealth to receive upfront and future payments linked to the achievement of regulatory, development and commercial milestones, and royalties on net sales of elamipretide in the licensed territories.
